Nucleus N5 CI500 series implant recall

Hard failure rate at a major cochlear implantation center

Authors

  • Douglas M. Hildrew MD,

    Corresponding author
    1. Department of Otolaryngology/ Head and Neck Surgery, Tulane University School of Medicine, New Orleans, Louisiana, U.S.A
    • Send correspondence to Douglas M. Hildrew, MD, 1430 Tulane Avenue, SL-59, New Orleans, LA 70112-2699. E-mail: dhildrew@tulane.edu

    Search for more papers by this author
  • Timothy B. Molony MD

    1. Department of Otolaryngology/ Head and Neck Surgery, Ochsner Clinic Foundation, New Orleans, Louisiana, U.S.A
    Search for more papers by this author

  • Original Clinical Research was collected from patient data at the Ochsner Clinic Foundation. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis

To compare the cumulative failure percentage of the Cochlear Nucleus N5 CI500 series implant observed, both before and after the voluntary recall of unimplanted devices, to that of the Cochlear Nucleus Freedom CI24RE series implant.

Study Design

Retrospective review of 411 patients implanted with either the Nucleus Freedom or the Nucleus N5 device.

Methods

Cochlear implantation was performed in standard fashion. A database was created by combining information obtained from operative case logs, an integrated clinical electronic medical records system, and an external database of devices maintained by Cochlear Corporation.

Results

Of the 289 implants of the Nucleus Freedom CI24RE series device at this institution, the cumulative failure percentage was 0%. There were 122 implants of the Nucleus N5 CI500 series device, yielding a 9.8% cumulative failure percent; 82 were manufactured before the voluntary recall and 40 were produced afterward. The 82 implants manufactured before the recall had two associated failures, while the 40 produced afterward had 10 failures.

Conclusions

It is possible that the cumulative failure percentage (CFP) of the Cochlear Nucleus N5 CI500 series implant is not fully defined. While the CFP of the Nucleus Freedom CI24RE series implant at this institution was 0%, it was 9.8% for the Nucleus N5. The CFP of Nucleus N5 devices manufactured before the voluntary recall was 2.4%, while the CFP afterward was 25.0%—nearly 6-fold higher than the company-published value of 4.2% for all Nucleus N5 implants registered globally.

Level of Evidence

3b. Laryngoscope, 123:2829–2833, 2013

Ancillary